MALVERN, Pa., April 23, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company"), a newly formed entity, today announced that it has successfully completed the previously announced acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization (the "Plan"). With the Plan's effectiveness, EIP's operating assets have exited the Chapter 11 financial restructuring process with significantly reduced outstanding indebtedness and resolution of EIP's pre-bankruptcy litigation overhang.
Following today's closing, Endo is poised for sustained growth and is strategically positioned to operate with a strong balance sheet, a broad, diversified portfolio of on-market medicines across its four segments, a deep pipeline of innovative and differentiated product candidates, and a highly skilled team.
"We believe Endo is well positioned to create value for our stakeholders over the long-term as we execute on our strategic priorities," said Blaise Coleman, Endo, Inc.'s President and Chief Executive Officer. "In particular, we are focused on growing our Branded Pharmaceuticals segment, anchored by XIAFLEX®, reviving growth in our Sterile Injectables segment through the launch of differentiated new products, and leveraging our improved balance sheet to drive new growth investments." Read more >
Through our long-standing work in endocrinology, orthopedics, and urology, as well as in hospital systems and with retail generic medications, we have developed an unmatched understanding of those we serve. We will never stop learning how to make a real difference in people's lives. We partner with hospitals and healthcare systems to reduce complexity through life-enhancing solutions, innovating together to add value where it matters—from manufacturing to treatment—so that healthcare providers can focus on patient care. We deliver high-quality, affordable generic medicines to patients in need through excellence in development, manufacturing, and commercialization. Drawing from over four decades of experience in the U.S. generic pharmaceutical market, we have built a well-established reputation for compliance and exceptional customer service.
This post is related to:
Community / Retail Pharmacy Resources Generics, Brand Name, Biotech Health System Pharmacy Resources
